Urological tumors
INCYTE INCB054828 (Principal Investigator: dr. J. Voortman)
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations.
Healthy men vs. prostate cancer patients (Principal Investigator: dr. A.J.M. van den Eertwegh)
Monitoring of DC and T cell functions in patients with prostate cancer treated with GM-CSF transduced allogeneic vaccines and anti-CTLA-4.
CAPRI (Principal Investigator: H. Westgeest)
Castration-resistant Prostate cancer RegIstry (CAPRI): an observational study in the Netherlands.
Viable (Principal Investigator: dr. A.J.M. van den Eertwegh)
A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAV/PCa versus placebo in men with metastatic castration resistant prostate cancer eligible for 1st line chemotherapy.
IMvigor010 / WO29636 (Principal Investigator: dr. J. Voortman)
A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection.
IMPACT mRCC (Principal Investigator: dr. C.W. Menke- van der Houven van Oordt)
Watchful waiting in patients with good and intermediate risk metastatic renal cell carcinoma; an imaging guided observational approach.
ROTOR14 (Principal Investigator: dr. A.J.M. van den Eertwegh)
Registry of Treatment Outcomes in a non-study population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223 (ROTOR-registry).
RECAB2 (Principal Investigator: dr. A.J.M. van den Eertwegh)
A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment.
CABAZIPET (Principal Investigator: dr. A.J.M. van den Eertwegh)
Towards early identification of response to cabazitaxel in patients with metastatic castration-resistant prostate cancer: potential of 18F-Choline PET-CT.
GALAHAD / Niraparib (Principal Investigator: dr. A.J.M. van den Eertwegh)
A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies.
WO39210 Atezolizumab (IMmotion010) (Principal Investigator: dr. A.J.M. van den Eertwegh)
This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.
Medimmune 2 (Principal Investigator: dr. J. Voortman)
A Phase 1 Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination with Immune Therapeutic Agents in Adult Subjects with Advanced Solid Tumors.